Tigermed Releases 2018 Annual Report
May 7, 2019
Tigermed (stock code: 300347) released its annual report 2018 on April 26, 2019.
According to the annual report, Tigermed maintained rapid growth in business performance in 2018. During the reporting period, the operating income reached RMB 2,300,659,700, a year-on-year increase of 36.37%, and the net profit attributable to the parent company reached RMB 472,183,900, a year-on-year increase of 56.86%.
Message from the Management
Due to the global innovation efforts and the reform of China’s pharmaceutical sector, investment in pharmaceutical R&D in China has grown rapidly, and a wealth of innovative products have been developed. The R&D environment in China articulates with the globally mature environment. Given China’s huge and rapidly growing pharmaceutical market, China is fast becoming the world-leading area for pharmaceutical R&D. For the CRO, a pharmaceutical R&D segment, best development opportunities emerge as Chinese innovative products go global and multinational enterprises’ innovative products move faster into the Chinese market.
As a local CRO company in China, Tigermed is committed to building one of the most influential CRO companies in the world based on its market development strategy of “Pursuing in-depth development in China and excellence in the world” and creating the global brand of “Tigermed”. In the past fifteen years, the company has always upheld the core values of integrity, pragmatism, dedication and cooperation, openness and inclusiveness, and stuck to high-quality standards and efficient cooperation to serve innovative pharmaceuticals, promote the launch of health products, and advance the human health.
Through the extension of the industrial chain and the capacity building for serving the regions, Tigermed has built an integrated and all-round research and development service platform for pharmaceutical and medical device clinical research, providing one-stop services for customers. Our clinical research and operations system has been validated by many rigorous verification processes, and our research capabilities are recognized by the launch of innovative products. Our team thrives under constant challenges. Our clinical research network in China has covered community-level hospitals, and the service network in the Asia Pacific region has been completed and put into operation.
In the next five years, Tigermed will seize the opportunity in China. While being oriented to customer needs and concentrating on globalization, Tigermed will build a global clinical service network, and acquire operations and management capabilities for global projects, providing integrated solutions and one-stop services for global R&D. We will continue to focus on the clinical research, stick to quality and compliance, and make each segment business bigger and stronger to achieve leapfrogging development. We will also take innovative development as our company’s central strategy, and focus on technological innovation in various business areas to enhance efficiency.
Talent is the most important resource of CRO. Tigermed attributes its rapid development to the selfless dedication of outstanding Tigermed people. In the future, we will continue to select, cultivate, use, and retain outstanding talents by building a platform more suitable for talent development, and creating a cultural atmosphere preferred by the outstanding talents. On this platform, the talents can realize self-worth while enhancing their professional competence.
Hangzhou Tigermed Consulting Co., Ltd（stock symbol: 300347） is a leading Contract Research Organization (CRO) in China dedicated to provide professional full clinical trial services. Since inception in 2004, Tigermed has been committed to accelerating medical product development with costs efficiency and quality. Headquartered in Hangzhou, Tigermed operates 32 subsidiaries, 95 offices across China and 12 overseas offices in Hong Kong China, Taiwan China, USA, Switzerland, Korea, Australia, Japan, Malaysia, Singapore , India and Romania with over 4100 full time staffs. Tigermed has serviced more than 600 local and global clients in the conduct of over 1060 clinical trials. Tigermed is recognized as “The Innovative CRO” in China，owning to our involvement of over 150 innovative drugs.